FDA Approves Anti-BCMA CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma
FDA Approves First Line KEYTRUDA® in Combination with Chemotherapy for Esophageal or Gastroesophageal Carcinoma
Advances with First-Line Dual Immunotherapies in Metastatic Non-Small Cell Lung Cancer
FDA Approves LIBTAYO® for Advanced Basal Cell Carcinoma
First Line KEYTRUDA® Superior to Chemotherapy in Metastatic MSI-H/dMMR Colorectal Cancer
Salvage YERVOY® and OPDIVO® Combination after Prior Immune Checkpoint Inhibitor Therapy in Advanced RCC
High Tumor Mutational Burden Predicts Response to KEYTRUDA®
FDA Approves KEYTRUDA® Plus Chemotherapy for Triple Negative Breast Cancer
Chemotherapy-Free First Line Induction and Consolidation Treatment for Acute Lymphocytic Leukemia
FDA Approves OPDIVO® plus YERVOY® for Malignant Pleural Mesothelioma
Immune Checkpoint Inhibitors Associated with High Activity in MSI-H Cancers
Optimal Duration of Immune Checkpoint Inhibitors in Advanced Non Small Cell Lung Cancer
OPDIVO® plus CABOMETYX® Combination Doubles Progression Free Survival in Newly Diagnosed Advanced Kidney Cancer
FDA Approves IO in Combination with Targeted Therapies for BRAF Positive Advanced Melanoma
FDA Approves KEYTRUDA® for Tumor Mutational Burden-High Solid Tumors
Overall Survival Benefit with Frontline OPDIVO® plus YERVOY® and Limited Chemotherapy in NSCLC
Late Breaking Abstract – ASCO 2020: FDA Approves BAVENCIO® for Maintenance Treatment in Advanced Urothelial Carcinoma
KEYTRUDA® Superior to ADCETRIS® in Relapsed or Refractory Classical Hodgkin Lymphoma
Late Breaking Abstract – ASCO 2020: First Line KEYTRUDA® Superior to Chemotherapy in Metastatic MSI-H/dMMR Colorectal Cancer
FDA Approves Chemotherapy-Free First Line Immunotherapy Combination in Advanced NSCLC
Bottom Ad
Advertisement
Subscribe
